NCT03488420Completed
Canadian EdoxAban(Lixiana®) Registry in Patients With ATrial Fibrillation/Flutter With Confirmed ValvUlar HeaRt DiseasE
Canadian EdoxAban (Lixiana®) Registry in Patients With ATrial Fibrillation and/or ATrial Flutter With Confirmed ValvUlar HeaRt DiseasE (CAPTURE)
Source: ClinicalTrials.gov · Last updated 6 Apr 2025
Brief summary (registry, in English)
The objective of this registry is the characterization of patients with atrial fibrillation (AF) and/ or atrial flutter (AFL) with confirmed VHD who are prescribed edoxaban in a real life clinical setting.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 136 (actual)
- First submitted
- 20 Mar 2018
- Start date
- 30 Apr 2019
- Primary completion date
- 21 Mar 2025
- Lead sponsor
- Montreal Heart Institute
- Diseases
- Atrial fibrillation
- NCT number
- NCT03488420
What you commit to
- Study type: Observational
- Participants enrolled: 136
- From 30 Apr 2019 to the primary completion date, 21 Mar 2025
- 9 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with a mechanical heart valve or rheumatic mitral stenosis, or moderate and severe non rheumatic mitral stenosis;
- Patients planned to have an intervention for valvular heart disease in the next 12 months;
Other
- Patients with AF and/or AFL secondary to reversible cause;
- Pregnant or breastfeeding women.
- Short term anticoagulation post cardioversion or ablation.
Who the study is looking for
- Male and female patients aged ≥ 18 years at baseline (signing of consent);
- Willing and able to provide written informed consent;
- Patient diagnosed or confirmed with AF and/or AFL within the last 12 months of signed consent form;
- Patient with VHD confirmed by echocardiography within the last 36 months of signed consent form except for mitral stenosis that must be confirmed within the last 12 months;
- Patient at risk for stroke in whom a long term oral anticoagulation is indicated and who are prescribed edoxaban.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CIUSSS de l'Estrie-CHUS-Centre Haute-Yamaska-hôpital de Granby Coordinator of this site? Confirm its status | Granby | Canada | Unknown status |
| CISSS de la Monteregie-Centre Coordinator of this site? Confirm its status | Greenfield Park | Canada | Unknown status |
| CISSS de Laval Coordinator of this site? Confirm its status | Laval | Canada | Unknown status |
| Montreal Heart Institute Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
| IUCPQ Coordinator of this site? Confirm its status | Québec | Canada | Unknown status |
| CISSS du Bas-Saint-Laurent/Hôpital Régional de Rimouski Coordinator of this site? Confirm its status | Rimouski | Canada | Unknown status |
| CISSS de Chaudière-Appalaches - Hopital Saint-Georges Coordinator of this site? Confirm its status | Saint-Georges | Canada | Unknown status |
| Centre Hospitalier Universitaire de Sherbrooke Coordinator of this site? Confirm its status | Sherbrooke | Canada | Unknown status |
| CIUSSS de la Mauricie-et-du-Centre-du-Quebec Coordinator of this site? Confirm its status | Trois-Rivières | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.